Sign in

You're signed outSign in or to get full access.

AT

Alaunos Therapeutics, Inc. (TCRT)·Q1 2023 Earnings Summary

Executive Summary

  • Q1 2023 was execution-focused: Alaunos advanced its TCR-T Library Phase 1/2 trial (actively enrolling; cryopreserved manufacturing underway), reiterated plans to deliver an interim multi-patient data update in Q3 2023, and strengthened its balance sheet by fully repaying its SVB term loan in May, leaving the company debt-free .
  • Financially, the quarter reflected development-stage status: no reported revenue, net loss of $10.0M and diluted EPS of $(0.04), with operating expenses up modestly YoY; operating cash burn was ~$9.4M as the company ramped manufacturing and enrollment .
  • Strategic catalysts were set: amended Precigen license eliminated commercial sales-based royalties and milestones (management cites >$160M potential savings), and hunTR throughput expansion supports adding three new TCRs in 2023 toward ~15 total .
  • Guidance maintained: 2023 operating cash outflows of $35–$40M and cash runway into Q4 2023; the Q3 interim update is the key near-term stock catalyst, with potential financing flexibility discussed on the call .

What Went Well and What Went Wrong

What Went Well

  • “Actively enrolling patients” with cryopreserved TCR-T products manufactured at viability/purity/TCR-positivity comparable to prior process; interim multi-patient clinical data expected in Q3 2023 .
  • Debt de-risking and license clean-up: “fully prepaid” SVB loan in May (was $11.0M at 3/31), releasing $13.9M restricted cash; Precigen amendment “eliminates all commercial sales-based royalties and milestone obligations” (management: “potential savings of over $160 million”) .
  • Platform and pipeline momentum: hunTR screening throughput increased with bioinformatics and AI adoption; plan to add three TCRs in 2023 (target ~15 total), supporting broader enrollment and possible multiplexing .

What Went Wrong

  • Operating spend increased with trial ramp: R&D rose 17% YoY to $6.5M; operating cash burn rose to ~$9.4M vs ~$7.8M in Q1 2022 as enrollment/manufacturing accelerated .
  • Continued lack of revenue in Q1 2023 (development-stage profile), net loss widened slightly to $10.0M vs $9.8M YoY; diluted EPS improved marginally to $(0.04) from $(0.05) .
  • Financing overhang: runway guidance into Q4 2023 puts a premium on the Q3 interim readout; management acknowledged opportunistic financing and sensitivity to dilution, underscoring dependence on clinical momentum .

Financial Results

Income Statement Summary (USD Millions unless noted)

MetricQ3 2022Q4 2022Q1 2023
Collaboration Revenue$2.911 $0.011 $0.000 (no revenue line; loss from operations equals total opex)
R&D Expense$7.893 $5.607 $6.504
G&A Expense$3.282 $2.925 $3.168
Total Operating Expenses$11.175 $8.532 $9.672
Interest Expense$0.841 $0.888 $0.853
Other Income (Expense), net$0.254 $0.250 $0.477
Net Loss$(8.851) $(9.159) $(10.048)
Diluted EPS ($)$(0.04) $(0.04) $(0.04)

YoY Comparison (Q1 2023 vs Q1 2022)

MetricQ1 2022Q1 2023Change
R&D Expense ($MM)$5.580 $6.504 +$0.924 (+17%)
G&A Expense ($MM)$3.505 $3.168 -$0.337 (-10%)
Total Operating Expenses ($MM)$9.085 $9.672 +$0.587
Interest Expense ($MM)$0.683 $0.853 +$0.170
Other Income (Expense), net ($MM)$(0.020) $0.477 +$0.497
Net Loss ($MM)$(9.788) $(10.048) -$0.260
Diluted EPS ($)$(0.05) $(0.04) +$0.01

Note: Margin metrics (gross/EBITDA/net margins) are not meaningful given immaterial/no revenue in Q4 2022–Q1 2023 .

Balance Sheet and Cash KPIs

KPIDec 31, 2022Mar 31, 2023
Cash & Cash Equivalents ($MM)$39.058 $23.496
Restricted Cash ($MM)$13.938 $13.938
Working Capital excl. Restricted ($MM)$15.695 $7.183
Total Assets ($MM)$64.937 $48.638
Total Stockholders’ Equity ($MM)$38.555 $29.509
Operating Cash Burn (Quarter, $MM)$7.1 (Q4 2022) $9.4 (Q1 2023)

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
Operating Cash Outflows ($MM)FY 2023$35–$40 $35–$40 Maintained
Cash RunwayFY 2023Into Q4 2023 Into Q4 2023 Maintained
Interim Clinical UpdateQ3 2023Mid-2023 multi-patient Q3 multi-patient interim Clarified timing to Q3
Patients to be Treated (Phase 1 total)CY 202312–15 total (3 dosed in 2022) 12–15 total (9–12 in 2023) Maintained
Debt Outstanding2023~$16.7M at 12/31/22; repay by Aug 2023 $11.0M at 3/31/23 fully prepaid in May; debt-free Lowered to $0 (post-Q1)
TCR Library Size2023Expanded +2 to 12; target 15 by YE Expect to add 3 new TCRs in 2023 (target ~15) Maintained trajectory

Earnings Call Themes & Trends

TopicPrevious Mentions (Q3’22 and Q4’22)Current Period (Q1’23)Trend
Trial Enrollment & Dose EscalationQ3’22: treating at dose level 2; momentum building Actively enrolling; interim Q3; 9–12 patients in 2023 to complete Phase 1; RPIs “fighting over” slots Accelerating enrollment and cadence
Manufacturing Capacity & CryopreservationQ3’22: doubled capacity; planned cryopreservation to cut time by 13% Cryopreservation implemented; multiple products manufactured; flexible scheduling; scaling for Phase 2 Operationalized; throughput rising
hunTR Platform & AI/BioinformaticsQ3’22: hunTR proof-of-concept; expanding screening for KRAS/TP53/EGFR Infrastructure expanded; “adoption of AI tools”; plan to add 3 TCRs in 2023 Higher throughput; pipeline expansion
Capital & RunwayQ4’22: follow-on $15M; runway into Q4’23 Debt fully repaid; restricted cash released; runway reiterated; opportunistic financing De-risked balance sheet; financing optionality
Regulatory & IND AmendmentsQ4’22: combined protocols; ended retest requirement; added 2 TCRs IND enhancements driving match rate and accrual; pursuing multiplexing/mbIL-15 next-gen Broader applicability; next-gen in view
Macro/Capital MarketsQ3’22: noneCommentary on follow-on market and bank failures; supportive capital markets noted Constructive external backdrop

Management Commentary

  • “We’ve been actively enrolling patients and manufacturing cryopreserved products, and we expect to report interim clinical data in the third quarter of this year… We are now moving forward unencumbered by debt or these potential royalties as we seek to transform the treatment of solid tumors.” — Kevin Boyle, CEO .
  • “This [Precigen] amendment eliminates all commercial sales-based royalties, and milestone obligations… potential savings of over $160 million.” — Kevin Boyle .
  • “As of March 31st 2023, Alaunos had approximately $37.4 million in total cash balances… operating cash outflows for 2023 excluding debt service costs… $35–$40 million… sufficient cash resources into the fourth quarter of 2023.” — Mike Wong, VP Finance .
  • “We recently expanded the infrastructure for our Hunter platform… adopting some AI tools and new equipment… greatly increases screening rates.” — Drew Deniger, VP R&D; Kevin Boyle .

Q&A Highlights

  • ASCO and interim readout: Management confirmed translational data from first three patients would be at ASCO; broader interim multi-patient efficacy/safety data planned for Q3, with venue flexible .
  • Enrollment targets and Phase 1 sizing: Guidance unchanged (12–15 total); 9–12 patients in 2023 to complete Phase 1; investigators strongly engaged .
  • Financing/runway: Company remains opportunistic, sensitive to dilution; reiterated runway into Q4 2023 and optionality for financing .
  • Manufacturing scale for Phase 2: Pursuing multi-pronged strategy (in-house, CDMO, hybrid) to expand capacity; cryopreservation improved scheduling; two-patient per run in Phase 1 .
  • IND enhancements driving accrual: Combined protocols, eliminated mutation retest requirement >6 months, and added cryopreservation—streamlining enrollment and increasing flexibility .

Estimates Context

  • Wall Street consensus (S&P Global) for Q1 2023 EPS and revenue was unavailable at time of query due to data access limitations; as a development-stage company, Alaunos did not report revenue in Q1 2023 and does not provide revenue/EPS guidance .
  • Implication: Without published consensus, the Q3 interim clinical readout and cash runway remain the primary drivers of estimate and rating changes.

Key Takeaways for Investors

  • Near-term catalyst: Q3 interim data on multiple TCR-T patients is pivotal for valuation and financing optionality; clinical signals on safety, persistence, and efficacy will drive the stock .
  • Execution momentum: Enrollment and manufacturing throughput are improving with cryopreservation; expect higher cadence of dosing and data flow through 2H 2023 .
  • Strategic de-risking: Full repayment of SVB debt and elimination of Precigen royalties/milestones strengthens long-term economics and partnering posture .
  • Pipeline breadth: Expanded TCR library (target ~15 in 2023) and hunTR throughput position Alaunos for broader indications and potential multiplexing strategies .
  • Cash discipline: Runway into Q4 2023 and operating outflows of $35–$40M maintained; watch for opportunistic financing aligned to positive data .
  • Trading lens: Expect heightened sensitivity to trial updates (ASCO translational data and Q3 interim); any evidence of durable responses or favorable safety at higher doses could create upside; delays or mixed signals would weigh on shares .
  • Medium-term thesis: If Q3 interim supports a recommended Phase 2 dose with compelling signals, Alaunos could advance into Phase 2 across multiple tumor types leveraging library flexibility and manufacturing scalability .